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Potassium homeostasis in renal failure
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Renal Laboratory, Department of Medicine, Cliniques UniversitairesSt-Pierre, Louvain, Belgium
The critical importance of serum potassium con-
centration in both health and disease has been dem-
onstrated more than a century ago when it was shown
that rapid i.v. injection of potassium salts caused
toxic and even fatal effects on the heart of the experi-
mental animal [I]. The role played by potassium in
the excitability of both nerve and muscle cells is now
well established.
Maintenance of a normal serum potassium concen-
tration depends to a large extent on renal function, as
more than 80% of the ingested potassium is excreted
in the urine. Surprisingly, however, serum potassium
level is kept within or slightly above normal limits
during most of the progressive course of renal failure.
Maintenance of potassium equilibrium despite a fall-
ing glomerular filtration reflects a progressive adapta-
tion of the mechanisms regulating serum potassium
concentration.
In the present paper we shall review the different
factors involved in the defense of potassium homeo-
stasis in renal failure: the adaptation of renal ex-
cretory mechanisms, the role of gastrointestinal ex-
cretion, the cellular tolerance to potassium load, the
resulting changes in potassium balance, and finally,
the complications which might alter potassium home-
ostasis in renal failure.
Renaladaptation
It has long been recognized that severe renal
insufficiency is associated with increased concen-
trations of serum potassium resulting in electro-
cardiographic and neurologic disorders, sometimes
severe enough to be lethal [2, 3]. Contrary to urea,
however, whose rise more or less parallels the
decline in renal function, serum potassium rises
above normal limits only at the ultimate stage of
renal failure [2—6]. Maintenance of a normal urinary
potassium excretion in the face of a falling glomeru-
lar filtration [7—9] implies that a progressively larger
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fraction of the filtered potassium appears in the urine
(Fig. I).
It was initially thought that potassium excretion
depends upon glomerular filtration, hyperkalemia
appearing only when dietary intake exceeds the fil-
tered load of potassium [4]. Leaf and Camara [8], in
careful studies of four patients with advanced renal
failure, established that urinary potassium output ex-
ceeds occasionally the filtered load of potassium, a
finding taken to indicate that urinary potassium is, at
least in part, secreted by the tubular cells. Sub-
sequently, it became clear that most of the urinary
potassium is derived from tubular secretion and not
from glomerular filtration [10]. The adaptation pre-
venting a rise of serum potassium concentration in
renal failure relies, thus, more on an enhanced tubu-
lar secretion than on a decreased tubular reabsorp-
tion of filtered potassium.
The intimate nature of the transport of potassium
by the nephron has been further defined during the
last decade. The present state of our knowledge is
discussed in detail by Wright in this symposium [II].
It has been shown that potassium reabsorption and
secretion vary from one nephron segment to another
and depend on a variety of factors such as peritubular
uptake of potassium mediated by the membrane so-
dium-potassium activated adenosine triphosphatases
(Na-K-ATPases), urine flow within the distal neph-
ron, the transtubular potential difference generated
by sodium transport and potassium pumps located
on the luminal side of tubular cells.
Localization and nature of enhanced renal excretion
of potassium. Most of our knowledge on potassium
excretion by the failing kidney has been obtained in
the experimental animal and, especially, in the sub-
totally nephrectomized dog or rat. In the dog, with a
remnant half kidney, Schultze et al [12] demonstrate
that potassium excretion per nephron increases four-
fold within 24 hr and six-fold within seven days after
removal of the heterolateral kidney. After a week, 24-
hr potassium excretion by the remnant kidney
reaches 87% of that achieved during the control pe-
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nod by the two kidneys (Fig. 2). Dogs maintained
constantly on large doses of 9-cr-fluorohydrocorti-
sone and adrenalectomized animals given a minimal
maintenance dose of DOCA undergo the same adap-
tive changes after 3/4 nephrectomy. This observa-
tion suggests that regulated changes in mineralo-
corticoid hormone activity are not essential for
adaptation to occur. Similarly, a persistent hyper-
kalemia is not a prerequisite since serum potassium
increases only by 0.8 mEq/liter 24 hr after nephrec-
tomy and returns to control values by day seven.
Modulations of distal sodium delivery after nephrec-
tomy do not play a crucial role either: adaptation is
the same whether the animal is given a low or a high
salt intake, a finding subsequently confirmed in rats
by Espinel [13]; moreover, urinary potassium excre-
tion is not modified by a reduction of distal sodium
delivery obtained by renal artery constriction of the
remnant kidney. These studies further demonstrate
that increased potassium excretion per nephron is
associated not with a reduced but rather with an
augmented acid secretion per nephron: overall so-
diuni cation exchange appears thus enhanced in the
remnant kidney. It might have been anticipated that
the failing kidney challenged by an acute potassium
load does not respond with as brisk a kaliuresis as a
normal kidney. This is obviously not the case in the
remnant kidney: hourly excretion of potassium after
a 25 mEq oral load is virtually the same as it was in
the control period.
In order to localize the sites of enhanced potassium
secretion, Bank and Aynedjian [141 carry out micro-
puncture and clearance experiments in rats in which
nephron reduction has been produced by 3/4 ne-
phrectomy. Just as in the dog model, equilibrium
between potassium intake and output is achieved
within 24 hr after nephron reduction and maintained
for up to two weeks. Micropunctures demonstrate
that both 24 hr and seven days after nephrectomy,
fractional reabsorption of potassium along the distal
tubule is closely comparable in control and 3/4 ne-
phrectomized rats: in neither case is there evidence
for tubular secretion of potassium. Approximately 4
and 7% of the filtered potassium enter the collecting
duct in the control and in the 3/4 nephrectomized
group, respectively, whereas final potassium excre-
tion reaches 7 and 59% of the filtered load in the two
groups, respectively. Most of the adaptive increase in
potassium secretion occurs, thus, along the collecting
duct. The reabsorptive pattern for potassium along
the distal tubule remains unaffected by stimuli, such
as suppression of dietary potassium intake or potas-
sium chloride infusion, resulting in a marked fall or
rise in urinary potassium output. Although the inter-
pretation of these results for the understanding of
distal tubular handling of potassium may be debated
[II], these data confirm that the collecting duct plays
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Fig. 1. Relationship between renal filnction (expressed hi serum
creatinine concentration) and fractional excretion of potassium (cx—
pressed as percentage of filtered potassium eliminated in the urine).
1 he heavy line represents the mean relationship between the two
parameters (percent of potassium excretion 8.6 X serum ereati-
nine in mg per 100 ml ). The fine lines delineate the area covered
by the standard deviation of These data document also
potassium secretion in severe renal failure, potassium excretion
exceeding the hltered load when serum creatinine exceeds ¶0 mg
per 100 ml (Reproduced from Platt 191.)
10
Serum creatinine, mg/lOO ml
Fig. 2. Adaptation in potassium excretion associated with nephron
reduction in the dog. Potassium excretion is measured Iirst with
both intact (hatched bar) and remnant (R) kidneys contributing to
renal function. The intact kidney is then removed and studies are
repeated. Potassium excretion by the remnant kidney increases
four-fold within 18 hr and six-fold within seven days after nephrcc-
tomy. Serum potassium (represented by closed circles) increases
transiently after the operation and returns to control values a week
later. (Reproduced from Schultze et al [121.)
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a central role in modulating urinary potassium excre-
tion by the remnant kidney.
The mechanism responsible for collecting duct ad-
aptation remains elusive. The micropuncture data are
obtained from rats given large amounts of aldoste-
rone. They confirm, thus, the conclusions of Schultze
et al [12] that modulation of aldosterone secretion
does not play a fundamental role in the adaptive
process. Distal delivery of water and sodium to the
collecting duct is increased 24 hr after nephron reduc-
tion and remains so, albeit to a lesser extent, two
weeks later. Although this augmented delivery of so-
dium and water might enhance potassium secretion
in the collecting duct, it is certainly not the sole
factor: chronic 3/4 nephrectomized rats given a po-
tassium-free diet do not exhibit collecting duct potas-
sium secretion, despite similar increases in distal
tubular flow.
Schultze et al [12] already pointed out the sim-
ilarity between the adaptation occurring in remnant
kidneys excreting a normal daily potassium intake
and that developing in normal kidneys challenged
with a sustained high potassium intake. This latter
phenomenon is extensively discussed by Silva,
Brown, and Epstein [15] in this symposium. Silva,
Hayslett, and Epstein [161 had demonstrated that
kidneys adapted to an increased potassium intake
have an augmented Na-K-ATPase activity. This en-
zyme is thought to be an essential element of the
active transport of sodium out of and potassium into
the cell interior. The hypothesis was therefore pro-
posed that the increased potassium secretion noted in
kidneys adapted to a high potassium intake resulted
from augmented Na-K-ATPase activity. Schon,
Silva, and Hayslett [17] explore the possibility that
nephron adaptation in the remnant kidney results
from a similar change in enzymatic activity. They
study rats which have undergone, at least two weeks
earlier, 3/4 nephrectomy. If the animals are main-
tained on a normal potassium intake, their fractional
potassium excretion increases markedly with a paral-
lel augmentation of Na-K-ATPase activity in both
the outer medulla and the cortex. By contrast, if the
rats are given a reduced potassium intake, neither
fractional excretion of potassium nor cortical and
medullary Na-K-ATPase activity increase. The rise in
Na-K-ATPase appears quite specific, as it is not ac-
companied by any change in magnesium activated
adenosine triphosphatase (Mg-ATPase) or in 5'-nu-
cleotidase activity. These data suggest that in renal
failure, just as in chronic potassium-loading, renal
adaptation results from an enhanced Na-K-ATPase
activity produced by an augmented urinary potas-
sium load.
Finkelstein and Hayslett [18] further investigate
the role of the collecting ducts' secretion and aug-
mented Na-K-ATPase in the adaptive process. They
compare the renal handling of potassium in a group
of 2/3 nephrectomized rats and in a group of rats
with unilateral nephrectomy and papillectomy of the
remnant kidney. Glomerular filtration is reduced by
35% in both groups. Two weeks after the operation
the serum potassium concentration is significantly
higher in the papillectomized rats than in the sub-
totally nephrectomized and in the control animals.
Challenged with an i.v. potassium load, the kidneys
of the subtotally nephrectomized animals increase
fractional excretion of potassium more than the pa-
pillectomized and control rats. The ability to excrete
potassium is correlated with the Na-K-ATPase con-
tent of the outer medulla: enzyme activity is aug-
mented by 25% in the subtotally nephrectomized but
unmodified in the papillectomized group.
Other factors, however, could influence potassium
homeostasis in renal failure. Natriuretic substances
have been isolated in renal failure patients [19, 20],
and it has been recently shown that they exert an
action on the collecting duct [21]. It will be of interest
in the future to evaluate whether they intervene also
in the adaptive increase in potassium secretion of
renal disease.
The reported experimental observations demon-
strate that subtotal nephrectomy is accompanied
within 24 hr by an augmented rate of potassium
excretion per nephron and by an enhanced kaliuresis
in response to a potassium load. This adaptive
change is located in the most distal parts of the neph-
ron. Hyperkalemia, modulation ofaldosteronesecre-
tion and distal sodium delivery do not play a critical
role. By contrast, an increased activity of Na-K-ATP-
ase in the medulla, induced perhaps by an aug-
mented urinary potassium load, appears to be of
critical importance.
The relevance of these data to the understanding of
the adaptation developing in human renal disease
remains to be determined. The model of subtotal
nephrectomy may not be representative of human
chronic renal disease. It is characterized by an aug-
mented single nephron glomerular filtration rate with
a resulting increase in the distal delivery of sodium
and water. By contrast, in experimental glomerulo-
nephritis [22, 23] and in toxic nephritis [24], single
nephron glomerular filtration rate is much more vari-
able, ranging from strikingly reduced to elevated val-
ues with parallel changes in distal filtrate delivery.
The remaining nephron after subtotal nephrectomy
undergoes an homogenous hypertrophy that is
strikingly different from that reported in glomerulo-
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nephritis [22, 23], pyelonephritis [25], toxic renal dis-
ease [24], and human renal disease [26].
It is likely that renal adaptation varies, to some
extent, from one model to another. This is illustrated
by Finkelstein and Hayslett's observation [18] that
the renal handling of potassium and the changes in
Na-K-ATPase are different if papillectomy is super-
imposed on subtotal nephrectomy. Similarly, it has
been recently reported that in experimental gb-
meruloncphritis Na-K-ATPase activity does not in-
crease [27].
Role of the renin-angiotensin-aldosterone system.
Aldosterone is a potent stimulus of tubular po-
tassium secretion. The possibility therefore has been
considered that an augmented aldosterone secretion
might contribute to the maintenance of potassium
balance in chronic renal failure.
As pointed out earlier, experimental evidence ob-
tained with models of remnant kidney does not sug-
gest that aldosterone plays such a role [12, 14]. Fur-
thermore, aldosterone production by adrenal tissue
measured in vitro is the same in subtotally nephrecto-
I
Sodium intake
mized and control rats [28]. In human renal disease,
increased aldosterone production does not seem to be
a critical element of the adaptive process. In 1963,
Cope and Pearson [29] report an increased aldoste-
rone secretion rate in 6 out of 12 uremic patients.
Their results, however, rely on several assumptions
about aldosterone metabolisni and are therefore dif-
ficult to interpret. More recently, Schrier and Regal
[30] study nine patients with stable renal failure
(mean creatinine clearance, 28 mI/mm). Aldosterone
excretion rate is normal if salt intake is adequate and
increases of sodium is restricted (Fig. 3). Similarly,
Weidman, Maxwell, and Lupu [31] and Weidman et
al [32] provide evidence that in patients with terminal
renal failure, plasma aldosterone concentration re-
mains normal as long as plasma renin activity and
serum potassium concentrations are within normal
limits. Increased serum potassium and/or plasma re-
nm levels, by contrast, are associated with elevated
plasma aldosteronc levels [3 1—33].
Although increased plasma aldosterone levels may
contribute to potassium homeostasis in renal failure,
these observations suggest that in human disease, just
as in the experimental animal, increased aldosterone
production is not indispensable for the maintenance
of potassium equilibrium in uremia. The demonstra-
tion that spironolactone given to patients with mild
renal failure [30] reduces potassium secretion sug-
gests, however, that normal levels of aldosterone are
required to avoid hyperkalemia. This conclusion is
supported by the observation of sustained hyper-
kalemia when hypoaldosteronism complicates the
course of renal failure [34].
Gastrointestinal excretion n/potassium
In normal subjects, potassium balance is main-
tained mainly by the kidney. The amount of potas-
sium lost in the feces represents a small proportion of
the dietary intake and is independant of its magni-
tude.
The digestive tract remains, however, a potentially
large source of potassium loss, as illustrated by the
potassium deficits produced by protracted diarrhea.
The possibility, therefore, has been considered that in
chronic renal failure, fecal excretion of potassium
might contribute significantly to potassium home-
ostasis.
Hayes et al [35] perform balance studies in 21
severely u remic patients (creatinine clearance, below
30 mI/mm), eight of whom are maintained on inter-
mittent hemodialysis. In control subjects on a normal
daily potassium intake (47 to 100 mEq/day), fecal
potassium excretion is less than 20% of the intake
(mean, 12%). By contrast, in patients whose creati-
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Fig. 3. Fileci of prolonged sodium restriction on aldosterone excre-
tion rate in nine patients with chronic renal disease (mean GFR. 28
nil nun 1. Aldosterone excretion was not increased in any of these
studies during the normal sodium intake (2 mEg/kg of body wt per
day for at least one week) but increased in each patient during
sodium restriction (10 to 21 mEg/day for 8 to 25 days). (Repro-
duced from Schrier and Regal [28].)
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nine clearance is below 5 mI/mm, stool potassium
output exceeds 20% of the intake (mean, 34%; range 7
to 76%). Intermediate values (mean, 18%; range, 15
to 24%) are noted when creatinine clearance ranges
from 10 to 30 mI/mm (Fig. 4). No difference is ob-
served between patients receiving a low or a normal
sodium intake. Fecal potassium output is related to
stool wet weight, although none of the patients have
diarrhea. These abnormalities are related to renal
failure per se, as they disappear after renal trans-
plantation. Similar observations of increased stool
potassium have been reported in patients with renal
failure [30, 36] although not constantly [37].
The understanding of the mechanisms responsible
for enhanced excretion of potassium by the gut is
hampered by the fact that concentration of elec-
trolytes in digestive fluids remains difficult to mea-
sure. Wrong et al [38] have developed an ingenious
method to obtain samples of the extracellular phase
of stool water. Cellophane capsules containing dcx-
tran are ingested by patients and collected sub-
sequently from their feces, filled with fluid whose
composition reflects that of stool water. Wilson et al
[39] utilize this method in 30 patients with acute or
chronic renal failure. Fecal dialysate composition dif-
fers markedly from control values: sodium concen-
tration falls from a mean of 19 mEq/liter in normal
subjects to 5 mEq/liter in uremics, whereas potas-
sium concentration rises from 77 to 125 mEq/liter
with a resulting fall in the sodium to potassium ratio.
Whereas Wilson et al [39] do not provide estimates
of glomerular filtration rate (GFR), it appears quite
clearly from the data of Hayes et al [35] (Fig. 4) that
fecal potassium output increases markedly only when
creatinine clearance drops below 5 ml/min. Even at
that stage the vicariant potassium excretion is not
very important (an average of 23 mEq/day for the
patients of Hayes et al and an average of 9 mEq/day
for the patients of Wilson et al). This amount might,
however, become critical at the very final stages of
renal failure when potassium intake is severely cur-
tailed, as might be the case in patients on a Giordano-
Giovannetti diet.
The experimental models used to study potassium
metabolism in renal failure do not have the markedly
lowered glomerular filtrations at which changes in
gut potassium excretion are observed in humans. It
is, therefore, not surprising that in dogs [12] whose
GFR has been reduced to 25% of normal, 93% of the
intake is excreted in the urine, just as in the control
period. Similarly, in rats with a GFR averaging 40%
of normal [14], 92% of the potassium intake is elimi-
nated by the kidney, versus 96% in the control ani-
m al s.
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Fig. 4.Re/ationship between renal Junction (expressed by creatinine
clearance) and stool potassium excretion (expressed as percentage n-
c/al/v potassium intake) in 23 patients with normal and reduced renal
function (66 balance periods). (CRE = chronic renal Jailure). Potas-
sium intake ranged from 47 to 100 mEq/day. It is noteworthy that,
independently of the sodium intake, stool potassium increases
markedly when creatinine clearance falls below 5 mI/mm. (Repro-
duced from Hayes et al [35].)
The mechanisms responsible for increased stool
potassium have not been completely elucidated. The
relationship noted between fecal potassium output
and stool weight [35] suggests that potassium reab-
sorption from the gut is decreased as a consequence
of a diminished intestinal water reabsorption. Alter-
natively, the possibility has been considered that the
high stool potassium results from hyperaldosteron-
ism. The decreased sodium to potassium ratio found
in uremic stool dialysate [39] is analogous to that
observed in normal subjects given mineralocorticoids
or patients with primary hyperaldosteronism [40].
Moreover, it is known that aldosterone stimulates
potassium secretion along the colon [41, 42].
This hypothesis remains open for discussion. As
pointed out earlier, there is no evidence that renal
failure is associated per se with an increased aldoste-
rone production. Hyperaldosteronism, is not unusual
however, in renal failure as a result of an aug-
mented renin level, an elevated serum potassium con-
centration, or a decreased extracellular volume [30,
32]. None of the studies reporting increased stool
potassium provide information on aldosterone levels.
Furthermore, the results of spironolactone adminis-
tration on stool electrolytes remain equivocal. Hayes
et al [35] report no effect of 100mg of spironolactone
given to three uremic subjects, a dose that might be
insufficient to inhibit the peripheral effects of aldoste-
rone. Wilson et al [39], on the other hand, note a
reversal of the sodium : potassium of stool dialysate in
8C
.
£
-
. if.
0. A 0
0 0
SAo 0.0
I I I I I It I I I
496 van Ypersele de Strihou
two patients given 300 mg of spironolactone. Results
however, are striking in only one case and debatable
in the other.
Finally, by analogy with the adaptive mechanisms
developing in animals fed a high potassium diet, it
may be suggested that the increased stool potassium
observed in renal failure results from an augmented
level of Na-K-ATPase in the colonic mucosa. It has
been demonstrated that chronic increases in potas-
sium intake in normal individuals result in aug-
mented fecal output of potassium and that this phe-
nomenon is associated with a raised level of Na-K-
ATPasc in the colon [431.
('el/u/ar tolerance to potassium loads
When given to normal subjects, a potassium load,
to a large extent, is taken up initially by the cells and
released slowly thereafter as renal excretion increases.
In animals adapted to a high potassium intake, this
cellular uptake is enhanced so that the changes in
serum potassium produced by an acute potassium
load are minimized [15, 44]. It might have been antic-
ipated that the adaptive increment in potassium ex-
cretion observed both in the uremic patients and in
experimental renal failure would be associated with a
parallel enhancement of the extrarenal uptake of p0-
t a ssi Um.
In uremic subjects, there is no evidence for such an
extrarenal adaptation. Winkler, Hoff, and Smith [7}
challenge five uremic subjects with 100 mEq of potas-
sium. The resulting increase in serum potassium is
larger than that noted in a normal subject. Keith and
Osterberg [45] obtain similar results in ten patients
with renal failure who were given 5 g of potassium
bicarbonate. The final concentrations of serum potas-
sium are substantially higher in uremic than in con-
trol subjects. In these early studies, neither basal po-
tassium intake nor the degree of renal failure are
accurately quantitated. More recently, however,
Gonick et al [46] have confirmed these findings: cellu-
lar potassium tolerance is not increased but rather is
decreased in renal failure.
This conclusion applies also to the animal with
experimental renal insufficiency. Schon, Silva, and
Hayslett [17] inject an i.v. load of potassium to sub-
totally nephrectomized rats. The rise in the serum
potassium (+2.8 mEq/liter) is significantly larger
than that observed in rats adapted to a high potas-
sium intake (+0.9 mEq/liter) but not significantly
different from that noted in normal rats (+ 1.8
mEq/Iiter). These results are confirmed by Finkel-
stein and l-Iayslett [18].
These data demonstrate a significant difference be-
tween the adaptative mechanisms associated with
chronic potassium loads and those observed in renal
failure. Extrarenal adaptation occurs only in the for-
mer situation, whereas renal adaptation can be dem-
onstrated in both models.
Body potassium stores in renal disease
The inability of the kidney to eliminate adequately
potassium may lead to an overall increase in body
potassium stores. On the other hand, the dietary re-
strictions associated with increasingly severe renal
failure, the loss of appetite, nausea, vomiting, and
diarrhea may induce weight loss, malnutrition, and
decreases of body potassium stores.
Several approaches have been used to ascertain
potassium stores in patients with renal failure: deter-
mination of exchangeable potassium, measurement
of total body potassium with a whole body scintilla-
tion counter, and tissue analysis. Elsewhere in this
symposium, Patrick [47] reviews these methods, their
limitations, and the pitfalls encountered in the inter-
pretation of their results.
I) Exchangeable potassium (Ke). In patients with
advanced chronic renal failure, variable results have
been obtained. Adesman et al [48] report a decreased
Ke per kg of body wt in three out of five uremic
patients, a finding confirmed by Spergel et al [491 in
an additional six patients. Patrick et al [50] find a
reduced Ke in six of nine patients with terminal
uremia, some of whom suffered from diarrhea, vom-
iting or having received diuretics. Similar observa-
tions are made by Bilbrey et al [51] in nine patients
maintained on a low protein diet. By contrast, Ber-
lyne, van Laethem, and Ben An [361 select carefully
13 severely uremic patients (mean creatinine clear-
ance, 4.1 mI/mm) without gastrointestinal distur-
bances, diuretic therapy, or cation exchange resins. In
this group, Ke is within normal limits.
Similar discrepancies are noted in patients treated
by chronic hemodialysis. Seedat [52] observes a 20 to
35% decrease of Ke in five out of seven patients
dialyzed for 14 to 42 hr per week with a solution
containing I mEq/liter of potassium. Ke falls pro-
gressively with the duration of the treatment. By con-
trast, Ram and Chisholm [53] note that Ke is initially
low in seven patients but returns towards normal
over the subsequent years, provided dialysis and pro-
tein intake are adequate. Rettori et al [54] explore
seven male patients dialyzed with a solution contain-
ing either I mEq/liter or no potassium. Ke is lower
than in control subjects, whether expressed per kg of
body wt, per kg of lean body mass, or per liter of
intracellular water.
Although the impression may be gained that these
data demonstrate potassium depletion in renal fail-
ure, several factors render their evaluation difficult.
First, the patient groups are very different from one
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another. Some studies [50] include debilitated pa-
tients with digestive problems, whereas others [36]
exclude them. In patients treated by chronic hemo-
dialysis, dialysate potassium content, dialyzer effi-
ciency, and duration of dialysis vary from one study
to another. Second, as emphasized by Patrick [47],
normal values of exchangeable potassium are not
well defined. These values are usually derived from
the relationship existing between Ke and body wt or
lean body mass (as evaluated from total body water)
[55]. This relationship varies with sex and age and is
likely to be distorted in renal failure, a condition
commonly associated with increased extracellular
fluid volume, even in the absence of edema [56]. Even
the use of intracellular water as a reference standard
[54] is questionable as it relies on the identity of
sulfate space and extracellular water, an assumption
which has not been validated in severe uremia. The
last difficulty in the assessment of Ke in uremic pa-
tients stems from the observation that the 24 hr,
allowed in most studies for radioactive potassium to
equilibrate with native potassium, may be in-
sufficient. Boddy et al [57] measure simultaneously
total body potassium with a whole body counter and
Ke after equilibration periods of 24, 48, and 64 hr in
12 patients with stable chronic renal failure. They
obtain increasing values of Ke, expressed as a per-
centage of total body potassium measured by whole
body counting: 60.7, 83.6, and 85.9% at 24,48, and 64
hr, respectively. They conclude that most studies us-
ing potassium 42 (42K) and a 24-hr equilibration
period underevaluate exchangeable potassium.
2) Total body potassium. In order to obviate the
problems inherent to delayed equilibration of radio-
active potassium, other investigators have resorted to
the measurement of the natural isotope potassium 40
(40K) by whole body counting techniques.
In stable chronic renal failure, total body potas-
sium remains within values predicted on the basis of
sex, age, height, and weight in 13 out of 15 uremic
patients (GFR ranging from 5 to 40 mI/mm) main-
tained on a low protein diet [57] and in eight severely
uremic patients (mean GFR, 8 mI/mm) studied by
Litteri et al [58]. In dialyzed patients, Morgan et al
[59] find no evidence of a total body potassium reduc-
tion in 21 subjects dialyzed against a bath containing
1.5 mEq/liter, whereas Johny et al [60] report signifi-
cantly reduced values in 5 out of 1 5 patients dialyzed
against a dialysate containing I to 1.4 mEq/liter.
Boddy et al [57] publish similar results: 4 of 18 pa-
tients dialyzed with a bath containing 1 mEq/liter of
potassium have a total body potassium below pre-
dicted values.
These data suggest that occasionally whole body
potassium is reduced. Whether this decrease repre-
sents a true deficiency or reflects merely a decreased
cellular mass resulting from malnutrition remains to
be established.
3) Cellular potassium content: a) Muscle ce/I analy-
sis. Bittar et al [61] report a normal cellular po-
tassium in two out of three muscle biopsies ob-
tained from severely uremic patients. Bergstrom
[62] observes a normal muscle cell potassium con-
tent in 13 out of 15 uremic patients (serum creati-
nine level, above 6 mg/lOO ml), an observation
confirmed by Graham, Lawson, and Linton [63] in
muscle biopsies obtained from 22 patients with renal
insufficiency (GFR ranging from 3 to 20 mI/mm).
In these studies intracellular potassium is expressed
as mEq per liter of intracellular water, a parameter
calculated as the difference between measured total
water and calculated extracellular water. The latter
quantity is assumed to equal chloride space. Since
chloride is supposed to be passively distributed across
the polarized cell membrane, this assumption is valid
only if a normal potential difference is maintained
across the cell membrane. Cunningham et al [641
have demonstrated that this assumption is not valid
in severely ill patients, including uremic subjects: un-
der these circumstances, the transmembrane poten-
tial difference falls. Bilbrey et al [51] confirm this
finding in patients with renal failure and use the
measured potential difference to calculate chloride
distribution across the cell membrane and, thus, the
extracellular water content. They report that in nine
patients, muscle cell potassium, expressed either per
liter of intracellular water or per 100 g of fat-free
solids, is lower than normal. Interestingly, these
values return to normal after initiation of dialysis.
These studies are based on biopsy material. But-
kus, Alfrey, and Miller [65], by contrast, analyze
tissue samples obtained at autopsy in 24 patients who
had been treated by hemodialysis. Cellular potassium
content of muscle or heart is significantly below con-
trol values whether potassium concentration is ex-
pressed per kilo of fat-free dry solids or per g of
nitrogen. Potassium content is more than two SD
below mean control levels in almost two-thirds of the
patients. The influence of dialysate composition on
cellular potassium stores is evidenced by the fact that
muscle potassium concentration is significantly lower
in subjects dialyzed with a potassium-free dialysate
than in those treated with a solution containing 2 to
2.6 mEq/liter.
b) Leukocyle composition. Patrick et al [50] and
Patrick and Jones [66] find that leukocyte potassium
content, expressed as mmoles per kg, is more than 1
SD below control mean values in 9 out of 16 patients
suffering from chronic renal failure.
This abnormality is fully corrected by chronic
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hemodialysis. It is of interest to note that the same
group has recently reported [67] a decreased sodium
efflux in uremic leukocytes, an abnormality also par-
tially corrected by hemodialysis. This finding is com-
patible with the hypothesis that the low leukocyte
potassium content reflects an abnormality of the
membrane ionic pump, rather than a true deficit cor-
rectable by an increased potassium intake.
c) Red blood cell composition. The erythrocyte is a
highly specialized cell which may not be representa-
tive of cells at large. It is nevertheless noteworthy that
Kramer, Gospodinov, and Kruck [68] observe a
lowered red blood cell potassium content in 2 out of
13 patients. They also note, in several of their sub-
jects, an increased red blood cell sodium content
associated with a decreased sodium efflux, an abnor-
mality already reported by Welt, Sachs, and
McManus [69]. This disorder has been ascribed to a
reduced activity of the membrane ouabain-sensitive
adenosine triphosphatases [70, 711 resulting from an
inhibitory factor present in uremic plasma. Indeed,
changes in red blood cell membrane enzymes can
be reproduced in normal red blood cells incubated in
uremic plasma [721. They disappear after hemodialy-
sis [69] or renal transplantation [73]. The hypothesis
that uremic toxins alter not only sodium hut also
potassium transport by the red blood cell, and
reduce occasionally red blood cell potassium content,
remains to be tested.
Johny et al [60] suggest that erythrocyte potassium
is a useful index of the direction and the magnitude of
changes in total body potassium. In 12 dialyzed pa-
tients, they observe a significant correlation between
red blood cell potassium and either total body potas-
sium or dialysis-induced changes in potassium bal-
ance, From their table, however, it appears that their
conclusions rest on a small number of patients: red
blood cell potassium is reduced in only 4 of their 12
patients, and total body potassium is decreased in
only three of them. Rettori et al [541, by contrast, do
not observe lowered red blood cell potassium content
in their dialyzed patients and find no correlation be-
tween exchangeable potassium and red blood cell
potassium content.
4) Conclusion. Evaluation of potassium stores is
clearly a difficult task. As pointed out by Patrick [47]
in this symposium, reduction of body potassium may
be encountered in three different conditions [74],
each of which occurs in uremic subjects. The first,
termed "potassium deficiency," refers to a cellular
loss of potassium, readily corrected by potassium
supplements. In the second, called "potassium deple-
tion," lowered cellular potassium stores cannot be
corrected by potassium supplements. In this state,
disturbed metabolic processes impair the cells' ability
to maintain a normal potassium content. The last
condition, "pseudo-depletion," is observed when to-
tal muscle mass is reduced: cellular potassium con-
centration is normal, and potassium supplements do
not return total body potassium to normal.
Nausea, vomiting, and steroid therapy in terminal
renal failure are probably associated, in some pa-
tients, with true potassium deficiency [50]. The cure
of digestive symptoms by appropriate dialysis and a
normal dietary potassium readily return cellular po-
tassium to normal. Potassium deficiency may also
develop when a protracted low potassium intake is
combined with prolonged hemodialysis with low po-
tassium bath [651. The incidence of this condition in
renal failure with or without dialysis cannot be eval-
uated for lack of balance data during potassium sup-
plementation.
The existence of potassium depletion in terminal
renal failure is suggested by the observations made on
red and white blood cells [67, 70, 711. The low cellular
potassium content might reflect the reduced mem-
brane Na-K-ATPase activity engendered by the accu-
mulation of toxic molecules in uremic serum. These
latter molecules might play a similar role in muscle
cells, reducing the transmembrane potential differ-
ence [511 and decreasing cellular potassium content.
Hemodialysis could improve cellular potassium
stores not only by allowing an augmented dietary
intake of' potassium hut also by enhancing cellular
potassium uptake [50, 51, 69].
Finally, pseudo-depletion is probably present in a
large number of patients maintained for prolonged
periods of time on a low protein diet with a resulting
malnutrition.
These different types of lowered potassium reserves
do probably coexist very often. The intricacies of
clinical settings combining inappropriate intake and
loss of potassium, impaired cellular potassium up-
take and decreased muscle mass, taken together with
the uncertainties of the diverse methods assessing
potassium stores, easily account for the apparently
contradictory results reported in the literature. At
any rate, all studies agree that serum potassium is not
correlated with potassium stores: this fact underlines
once more how little serum potassium reflects the
actual state of total body potassium.
The clinical consequences of reduced body potas-
sium reserves have not been clearly defined. Altered
glucose tolerance [49] and disturbed cardiac function
[651 are likely complications of potassium deficiency.
Pseudo-depletion on the other hand, is not expected
to lead to such disorders, whereas the effect of potas-
sium depletion remains to be demonstrated.
Potassium homeostasis in renal failure 499
Factors interJring with the adapt ative mechanisms
regulating serum potassium in renal Jailure
The development of hyperkalemia during the ulti-
mate phase of renal failure signifies that despite its
adaption, renal function fails to maintain a normal
potassium excretion.
Several events may precipitate hyperkalemia be-
fore these final limits are reached. We shall consider
them briefly.
A Iterations of the intra-extracellular distribution of
potassium: I) Acid-base disturbances. Burnell et al.
[751 have demonstrated that in man, changes in
acid-base balance alter serum potassium concentra-
tions independently of total body potassium: acidosis
increases, whereas alkalosis decreases serum potas-
sium, every 0.1 U change in extracellular pH eliciting
an inverse 0.6 niEq/liter change in serum potassium
concentration. These alterations in serum potassium
concentration depend solely on extracellular pH
modifications [76]. They result from a redistribution
of potassium across the cellular membrane. This
phenomenon is readily observed in patients with
renal failure [77] who are prone to develop metabolic
acidosis. Correction of acidosis may return to normal
an alarmingly high serum potassium concentration
[78, 79].
2) Arginine. A similar redistribution of potassium
between extracellular and intracellular spaces has
been recently invoked to account for the hyperka-
lemia elicited in uremic patients by the infusion of
arginine hydrochloride [80]. Arginine, just as other
cationic amino acids, penetrates cells and displaces
potassium [81] towards the extracellular space. The
resulting hyperkalemia is mild if renal function is
adequate but potentially lethal in severe renal failure.
3) Serum hyperosmolality. Acute increases in serum
osmolality may also provoke a redistribution of po-
tassium across cell membranes. Seldin and Tarail [82]
have demonstrated that sudden augmentation of se-
rum glucose is accompanied by an outward move-
ment of cellular potassium and water. Makoff et al
[83, 84] report similar observations in dogs whose
extracellular osmotic pressure has been augmented
by mannitol. In isolated muscle cells, elevation of
bath medium glucose content reduces intracellular
potassium [85]. In diabetic patients with a failing
renal function, sudden hyperglycemia may lead to
severe hyperkalemia [86].
Alterations of renal adaptation: 1) Aldosterone. As
already pointed out, there is no evidence that in-
creased aldosterone secretion is part of the adaption
required to maintain potassium homeostasis in
chronic renal failure.
Recently, however, it has become evident that a
normal plasma level of aldosterone is indispensable
for the maintenance of a normal serum potassium
level in patients with chronic renal disease. In 1968,
Gerstein et al [34], reported the occurrence of severe
hyperkalemia, sodium wasting, and an inability to
acidify the urines in a patient with non-oliguric renal
failure. Hypoaldosteronism is documented. Replace-
ment therapy with mineralocorticoids corrects the
electrolyte and acid-base disorders. Several similar
patients have been reported since, all of whom have
in common sustained hyperkalemia despite a normal
potassium intake and a moderate degree of renal
failure [87—92]. Interestingly, most of these patients
are above 50 years in age, and a large proportion of
them suffer from diabetes [87]. Although plasma re-
nm levels were initially reported to be normal, it
became rapidly apparent that hypoaldosteronism is
commonly associated with hyporeninemia [87—90].
The observation that replacement therapy with
mineralocorticoids promptly increases kaliuresis and
returns serum potassium to normal suggests strongly
that hyperkalemia is caused by the deficient aldoste-
rone secretion. Several factors have been considered
to account for hypoaldosteronism. A selective defi-
ciency in the response of aldosterone secretion to
serum potassium concentrations seems unlikely. Al-
though potassium is a direct stimulus of aldosterone
secretion [93—95], there is good evidence that aldoste-
ronc responsiveness to a variety of other more potent
stimuli is also decreased or abolished: adrenocorti-
cotropic hormone [87—91, 96], angiotensin II [34,
87—89, 91, 92], catecholamines [87, 88], or a salt-free
diet [34, 86, 87, 89—91].
Alterations in the biosynthesis of aldosterone is
also improbable. Although such a defect has been
recently documented in two cases of hypoaldosteron-
ism associated with renal disease [96], it is absent in
most others [87, 88, 90]. Furthermore, such enzyme
defects are usually associated with elevated rather
than lowered renin levels [97].
The most likely cause of hypoaldosteronism seems
to be the lowered serum renin level with a resultant
decrease in angiotensin II generation, a situation also
encountered in anephric patients without measurable
plasma renin levels [31, 98, 99]. In the case of hypo-
aldosteronism, response of plasma renin levels to
several stimuli, such as upright posture [87, 89, 901,
catecholamine infusion [87, 88], furosemide injection
[89—91], or salt-free diet [87—91] is blunted or absent.
The cause of the lowered plasma renin level has not
been completely elucidated. Hyperkalemia, a mild
suppressor of renin secretion [100, 101], does not
appear to play a significant role, since correction of
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hyperkalemia with a cation exchange resin [88, 90]
does not elevate the plasma renin level. The altered
release of renin may result from specific alterations of
the j uxtaglomerular apparatus developing during the
course of renal disease. This hypothesis is compatible
with the observations [102, 1031 that the plasma renin
level and its responsiveness to a low salt diet vary
according to the type of renal disease, being lower in
pyelonephritis and polycystic kidney disease than in
glomerulonephritis. Another explanation has been
proposed more recently by Dc Leiva et al [961. They
observe two diabetic patients with mild renal failure
and hyporeninemic hypoaldosteronism and note that
the lowered plasma renin levels are associated with an
elevated level of the renin precursor prorenin. They
propose that, in these cases, hyporeninemia results
from an impaired conversion of prorenin into renin.
Whether this attractive hypothesis applies to all cases
of hyporeninemic hypoaldosteronism remains to be
determined. It is noteworthy, however, that increased
levels of prorenin are not unusual in diabetic nephro-
pathy and chronic renal disease [104], a finding com-
patible with the hypothesis that a defective transfor-
mation of prorenin is the first sign of hyporeninemic
hypoaldosteronism.
As an alternative explanation for hyporeninemia,
Oh et al [91] have suggested that it is not a pathologic
feature but rather reflects a physiologic suppression
of the enzyme by an augmented extracellular volume.
In support of their hypothesis, they draw attention to
the fact that most reported cases of hyporeninemic
hypoaldosteronism are hypertensive and that, in two
of their own patients, continued administration of
furosemide increases both plasma renin and aldoste-
rone. The effect of these maneuvers on serum potas-
sium is not reported. This explanation appears diffi-
cult to reconcile with the general observation that
patients with hypoaldosteronism have a tendency to
be salt wasters and that sustained salt restriction
leads usually to a further increase in serum potas-
5! U Ill.
2) Insulin. The role of insulin in potassium home-
ostasis has been recently recognized [105—109]. In-
creases in serum potassium trigger the release of in-
sulin by the pancreas [108—1101, whereas in turn,
insulin stimulates cellular potassium uptake
[111—113]. A deficiency of this feedback mechanism
in the presence of an impaired renal excretion of
potassium might produce hyperkalemia. This hy-
pothesis could account for the susceptibility to hy-
perkalemia of diabetic patients receiving potassium-
sparing diurectics [114—115], aldosterone antagonist
[116], or suffering from hypoaldosteronism [86] and
renal failure (VAN YPERSELF. i)E STRII-lou, VAN-
DENBROUCKE, unpublished data).
3) Tubular resistance of renal tubules to miner-
alocorticoid action. Hypoaldosteronism or its associa-
tion with diabetes probably accounts for several cases
of unexplained hyperkalemia observed in non-oh-
guric renal disease [117]. In some other patients, hy-
perkalemia results apparently from a tubular unre-
sponsiveness to mineralocorticoids. Luke, Allison,
and Davidson [118] describe hyperkalemia in a pa-
tient with renal failure due to amyloidosis. The al-
tered renal excretion of potassium is not corrected by
mineralocorticoid therapy. Similarly, Popovizer et al
[119] observed a patient with salt-wasting neph-
ropathy and hyperkalemia, despite adequate aldoste-
rone secretion. Resistance of the tubules to the pe-
ripheral effects of mineralocorticoids is further
documented by the failure of DOCA injections to
augment urinary potassium output.
4) Spironolactone. potassium-sparing diuretics. In-
hibition of distal potassium secretion as a result ei-
ther of aldosterone antagonists or of potassium-spar-
ing diuretics may dramatically impair potassium
excretion in renal failure and produce severe hy-
perkalemia [34, 116, 120].
Increased loads oJ potassium. As stated earlier, the
tolerance to exogenous potassium loads is decreased
in renal failure as a result of a reduced extrarenal
uptake of potassium and an impaired potassium ex-
cretion. Sudden increases in potassium load, there-
fore, may lead to hyperkalemia and, occasionally,
cardiac arrest.
1) Exogenous potassium loads. Potassium supple-
ments prescribed in association with diuretics, potas-
sium salts used as substitutes for sodium chloride in
sodium-free diets, consumption of low sodium (high
potassium) milk [121] may all precipitate lethal hy-
perkalemia.
2) Endogenous potassium loads. Catabolism asso-
ciated with trauma, infections, or high fever may
release massive amounts of cellular potassium and
produce potassium intoxication. The catabolism of
100 g of muscle protein liberates 44 mEq of potas-
sium [122]. A massive release of cellular potassium is
also the cause of the hyperkalemia encountered occa-
sionally after succinyichohine administration to pa-
tients with neuromuscular disorders [123].
Conclusions
Potassium homeostasis is remarkably maintained
throughout the evolution of renal disease up to the
ultimate stages of renal insufficiency. The kidney re-
mains the main organ regulating potassium balance
and serum potassium concentrations, despite losses
of up to 80 to 90% of its mass.
Potassium excretion is maintained through an aug-
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mented tubular secretion, localized, at least in some
experimental models, in the most distal parts of the
nephron where it is associated with an augmented
activity of Na-K-ATPase. Enhanced tubular secre-
tion of potassium is certainly improved by increased
levels of aldosterone resulting from hyperkalemia,
dehydration, or increased renin levels, although an
augmented rate of aldosterone secretion is neither a
prerequisite for potassium homeostasis to be main-
tained nor a necessary element of renal failure.
In severe renal failure, gastrointestinal excretion of
potassium may increase and contribute to the mainte-
nance of potassium balance. Its mechanism is not yet
clear, and more data will be necessary to evaluate the
role of aldosterone, colonic enzyme activity, etc.
Adaptation of renal and digestive excretion of po-
tassium are not accompanied by a parallel improve-
ment in cellular uptake. On the contrary, cellular
tolerance to potassium loads is decreased. As a result,
increases in potassium intake may produce lethal lev-
els of serum potassium.
Overall balance of potassium in renal failure varies
markedly from patient to patient and is difficult to
assess by currently available methods. Decreased
dietary intake and digestive intolerance to potassium,
increased loss due to dialysis with low potassium
baths may lead to potassium deficiency that can be
repaired by appropriate maneuvers. Uremic serum
might also contain toxic molecules capable of inhib-
iting electrolyte transport by the cellular membrane.
Consequently, cellular potassium might drop and re-
sult in a potassium depletion resistant to an aug-
mented potassium intake. Finally, malnutrition may
so reduce muscle cell mass that total body potassium
falls and produces pseudo-depletion.
The delicate mechanisms maintaining potassium
homeostasis in renal failure may be disrupted by
several factors and lead to hyperkalemia. The
gradient between intracellular and extracellular po-
tassium is modified by acidosis, cationic amino acids,
and sudden increases in plasma osmolality. Absence
of aldosterone, resistance of renal tubules to mm-
eralocorticoids, inhibition of tubular transport of
potassium by spironolactone and potassium-sparing
diuretics, may jeopardize the adaptive increases in
tubular potassium secretion. Lack of insulin asso-
ciated with an impaired renal excretion of potassium
may diminish the cellular tolerance to potassium
loads and result in brisk hyperkalemia. Finally, an
increased endogenous or exogenous load of potas-
sium may precipitate potassium intoxication.
Reprint requests to Dr. C'. ran Ypersele de Strihou, Renal Labora-
/0ev, Department 01 Medicine, Cliniques Universitaires St- Pierre,
Louvain, Belgium.
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